Repurposing approved drugs may be beneficial in Leishmaniasis treatment
Researchers at the University of Pennsylvania School of Veterinary Medicine (Philadelphia, PA, USA) have suggested that CD8+ T cell-induced pathology in Leishmaniasis, depends on NLRP3 inflammasome activation and IL-1β signaling. Therefore, inhibiting these with FDA approved drugs may provide therapeutic benefit for Leishmaniasis patients.
Please sign in or register for FREE
Sign in to RxNet
Register to RxNet
RxNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.